Short Interest in Oragenics, Inc. (NYSEAMERICAN:OGEN) Decreases By 22.3%

Oragenics, Inc. (NYSEAMERICAN:OGEN) was the target of a large decline in short interest during the month of December. As of December 31st, there was short interest totaling 108,196 shares, a decline of 22.3% from the December 15th total of 139,273 shares. Approximately 2.9% of the shares of the company are sold short. Based on an average daily trading volume, of 70,912 shares, the short-interest ratio is presently 1.5 days. Based on an average daily trading volume, of 70,912 shares, the short-interest ratio is presently 1.5 days. Approximately 2.9% of the shares of the company are sold short.

Oragenics Stock Performance

Shares of OGEN stock traded up $0.01 on Friday, reaching $0.95. The stock had a trading volume of 30,191 shares, compared to its average volume of 50,174. Oragenics has a 1 year low of $0.74 and a 1 year high of $18.90. The stock has a market cap of $3.96 million, a P/E ratio of -0.08 and a beta of 0.90. The company has a 50 day simple moving average of $0.91 and a 200 day simple moving average of $1.14.

Oragenics (NYSEAMERICAN:OGEN) last posted its quarterly earnings data on Friday, November 7th. The company reported ($1.96) EPS for the quarter.

Institutional Trading of Oragenics

Several large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its holdings in Oragenics by 7,374.0% during the second quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock valued at $59,000 after buying an additional 15,338 shares during the last quarter. Sabby Management LLC purchased a new position in shares of Oragenics during the 3rd quarter worth $77,000. Finally, Clear Street LLC bought a new stake in shares of Oragenics during the 2nd quarter valued at $270,000. 18.71% of the stock is currently owned by institutional investors.

About Oragenics

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.